BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 35979372)

  • 1. Regulatory T cells (Tregs) in lymphoid malignancies and the impact of novel therapies.
    Maharaj K; Uriepero A; Sahakian E; Pinilla-Ibarz J
    Front Immunol; 2022; 13():943354. PubMed ID: 35979372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis.
    Kumar P; Saini S; Prabhakar BS
    Semin Cancer Biol; 2020 Aug; 64():29-35. PubMed ID: 30716481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treg Fragility: A Prerequisite for Effective Antitumor Immunity?
    Overacre-Delgoffe AE; Vignali DAA
    Cancer Immunol Res; 2018 Aug; 6(8):882-887. PubMed ID: 30068755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer.
    Revenko A; Carnevalli LS; Sinclair C; Johnson B; Peter A; Taylor M; Hettrick L; Chapman M; Klein S; Solanki A; Gattis D; Watt A; Hughes AM; Magiera L; Kar G; Ireland L; Mele DA; Sah V; Singh M; Walton J; Mairesse M; King M; Edbrooke M; Lyne P; Barry ST; Fawell S; Goldberg FW; MacLeod AR
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35387780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells.
    Alissafi T; Hatzioannou A; Legaki AI; Varveri A; Verginis P
    J Autoimmun; 2019 Nov; 104():102310. PubMed ID: 31421963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treg-mediated acquired resistance to immune checkpoint inhibitors.
    Saleh R; Elkord E
    Cancer Lett; 2019 Aug; 457():168-179. PubMed ID: 31078738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of Tregs on the Anticancer Immunity and the Efficacy of Immune Checkpoint Inhibitor Therapies.
    González-Navajas JM; Fan DD; Yang S; Yang FM; Lozano-Ruiz B; Shen L; Lee J
    Front Immunol; 2021; 12():625783. PubMed ID: 33717139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Canonical Secretomes, Innate Immune Caspase-1-, 4/11-Gasdermin D Non-Canonical Secretomes and Exosomes May Contribute to Maintain Treg-Ness for Treg Immunosuppression, Tissue Repair and Modulate Anti-Tumor Immunity
    Ni D; Tang T; Lu Y; Xu K; Shao Y; Saaoud F; Saredy J; Liu L; Drummer C; Sun Y; Hu W; Lopez-Pastrana J; Luo JJ; Jiang X; Choi ET; Wang H; Yang X
    Front Immunol; 2021; 12():678201. PubMed ID: 34084175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
    Sasidharan Nair V; Elkord E
    Immunol Cell Biol; 2018 Jan; 96(1):21-33. PubMed ID: 29359507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy.
    Wang H; Franco F; Ho PC
    Trends Cancer; 2017 Aug; 3(8):583-592. PubMed ID: 28780935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B.
    Gao Y; You M; Fu J; Tian M; Zhong X; Du C; Hong Z; Zhu Z; Liu J; Markowitz GJ; Wang FS; Yang P
    J Hepatol; 2022 Jan; 76(1):148-159. PubMed ID: 34689996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer.
    Taylor NA; Vick SC; Iglesia MD; Brickey WJ; Midkiff BR; McKinnon KP; Reisdorf S; Anders CK; Carey LA; Parker JS; Perou CM; Vincent BG; Serody JS
    J Clin Invest; 2017 Sep; 127(9):3472-3483. PubMed ID: 28825599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of CD4
    Hariyanto AD; Permata TBM; Gondhowiardjo SA
    Immunol Med; 2022 Jun; 45(2):94-107. PubMed ID: 34495808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging Functions of Regulatory T Cells in Tissue Homeostasis.
    Sharma A; Rudra D
    Front Immunol; 2018; 9():883. PubMed ID: 29887862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Markers of Regulatory T Cells in Cancer Immunotherapy with Special Focus on Acute Myeloid Leukemia (AML) - A Systematic Review.
    Kaboli PJ; Zhang L; Xiang S; Shen J; Li M; Zhao Y; Wu X; Zhao Q; Zhang H; Lin L; Yin J; Wu Y; Wan L; Yi T; Li X; Cho CH; Li J; Xiao Z; Wen Q
    Curr Med Chem; 2020; 27(28):4673-4698. PubMed ID: 31584362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Targeting of Tumor-Infiltrating Regulatory T Cells in Breast Cancer.
    Fattori S; Roux H; Connen E; Robert L; Gorvel L; Le Roy A; Houacine J; Foussat A; Chretien AS; Olive D
    Cancer Res; 2022 Nov; 82(21):3868-3879. PubMed ID: 36040356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roles of regulatory T cells in cancer immunity.
    Takeuchi Y; Nishikawa H
    Int Immunol; 2016 Aug; 28(8):401-9. PubMed ID: 27160722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolation and Analysis of Tumor-Infiltrating Treg.
    Bergerhoff K; Pedersen M
    Methods Mol Biol; 2023; 2559():51-63. PubMed ID: 36180626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induced regulatory T cells in inhibitory microenvironments created by cancer.
    Whiteside TL
    Expert Opin Biol Ther; 2014 Oct; 14(10):1411-25. PubMed ID: 24934899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment.
    Granito A; Muratori L; Lalanne C; Quarneti C; Ferri S; Guidi M; Lenzi M; Muratori P
    World J Gastroenterol; 2021 Jun; 27(22):2994-3009. PubMed ID: 34168403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.